Bristol-Myers Squibb Company (BMY) Balance Sheet

NYSE: BMYAssets, liabilities, debt and equity over 10 years.

BMY balance sheet, 2025

December 31, 2025 · U.S. dollars

$90.04B assets = $71.53B liabilities + $18.51B equity

What it owns$90.04BCash & ST investments: $10.67B (11.9%)Cash & ST investments$10.67B · 12%Receivables: $14.53B (16.1%)Receivables$14.53B · 16%Inventory: $2.69B (3.0%)Other current: $1.50B (1.7%)PP&E: $9.12B (10.1%)PP&E $9.12BGoodwill & intangibles: $40.86B (45.4%)Goodwill & intangibles$40.86B · 45%LT investments: $2.51B (2.8%)Other non-current: $8.16B (9.1%)Other non-current $8.16B=How it is financed$90.04BCurrent liabilities: $23.42B (26.0%)Current liabilities$23.42B · 26%Long-term debt: $42.85B (47.6%)Long-term debt$42.85B · 48%Other LT liabilities: $5.26B (5.8%)$5.26BShareholders’ equity: $18.51B (20.6%)Shareholders’ equity$18.51B · 21%

Both columns are drawn to the same scale: what BMY owns equals what it owes plus shareholders’ equity. Hover a block for its value.

BMY financial health

Current ratio1.26
Adequate · current assets cover current liabilities 1.26×
Debt / equity2.55
High leverage · $2.55 of debt for each $1 of equity
Equity / assets20.5%
Balanced · of assets funded by shareholders
Cash / debt22.6%
Low cash cover · cash & short-term investments vs total debt
Goodwill & intangibles45.4%
Acquisition-heavy · of total assets

Descriptive bands, not a rating. Fiscal 2025.

BMY balance sheet trends, 2016–2025

Bristol-Myers Squibb Company balance sheet trends
MetricTrendThenLatestChange
Total assets$33.71B2016$90.04B2025+11.5%/yr
Total liabilities$17.36B2016$71.53B2025+17.0%/yr
Shareholders’ equity$16.18B2016$18.47B2025+1.5%/yr
Cash & short-term investments$6.35B2016$10.67B2025+5.9%/yr
Total debt$6.71B2016$47.14B2025+24.2%/yr
Net cash (debt)−$358.0M2016−$36.47B2025−$36.1B
Working capital$4.86B2016$5.97B2025+$1.1B
Book value per share$9.632016$9.052025−0.7%/yr
Current ratio1.5520161.262025−0.29
Debt / equity0.4120162.552025+2.14
Shares outstanding1.68B20162.04B2025+2.2%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

BMY assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

BMY liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

BMY debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

BMY balance sheet

Bristol-Myers Squibb Company annual balance sheet
2025202420232022202120202019201820172016
Assets
Cash & short-term investments$10.67B$10.86B$12.28B$9.25B$17.22B$16.45B$15.39B$8.76B$6.81B$6.35B
Cash & equivalents$10.21B$10.35B$11.46B$9.12B$13.98B$14.55B$12.35B$6.91B$5.42B$4.24B
Short-term investments$464.0M$513.0M$816.0M$130.0M$3.24B$1.90B$3.05B$1.85B$1.39B$2.11B
Receivables$14.53B$14.42B$15.26B$13.94B$12.52B$10.55B$7.68B$5.75B$6.30B$5.54B
Inventory$2.69B$2.56B$2.66B$2.34B$2.10B$2.07B$4.29B$1.20B$1.17B$1.24B
Other current assets$1.50B$1.94B$1.56B$1.74B$1.43B$1.11B$1.98B$2.02B$576.0M$570.0M
Total current assets$29.39B$29.78B$31.77B$27.27B$33.26B$30.19B$29.35B$17.72B$14.85B$13.70B
Property, plant & equipment (net)$9.12B$8.36B$8.04B$7.47B$6.97B$6.75B$6.96B$5.03B$5.00B$4.98B
Goodwill & intangible assets$40.86B$45.36B$48.65B$57.50B$63.28B$74.00B$86.46B$7.63B$8.07B$8.26B
Long-term investments$2.51B$2.51B$2.06B$2.19B$2.71B$433.0M$767.0M$1.77B$2.48B$2.72B
Other non-current assets$8.16B$6.59B$4.64B$2.38B$3.09B$7.12B$6.41B$2.84B$3.14B$4.04B
Total assets$90.04B$92.60B$95.16B$96.82B$109.31B$118.48B$129.94B$34.99B$33.55B$33.71B
Liabilities
Accounts payable$3.58B$3.60B$3.26B$3.04B$2.95B$2.71B$2.44B$1.89B$2.25B$1.66B
Short-term debt$2.46B$2.23B$3.28B$4.40B$5.12B$2.50B$3.48B$1.70B$987.0M$992.0M
Deferred revenue——$271.0M$1.34B$3.69B$3.62B$4.49B$172.0M$83.0M$762.0M
Total current liabilities$23.42B$23.77B$22.26B$21.89B$21.87B$19.08B$18.30B$10.65B$9.56B$8.84B
Long-term debt$42.85B$47.60B$36.65B$35.06B$39.60B$48.34B$43.39B$5.65B$6.97B$5.72B
Lease obligations$2.03B$1.55B$1.69B$1.40B$1.04B$997.0M$805.0M———
Other long-term liabilities$5.26B$4.84B$6.76B$8.76B$11.84B$13.18B$16.55B$4.56B$5.17B$2.80B
Total liabilities$71.53B$76.22B$65.67B$65.70B$73.31B$80.60B$78.25B$20.86B$21.70B$17.36B
Shareholders' equity
Common stock & paid-in capital$292.0M$292.0M$292.0M$292.0M$292.0M$292.0M$292.0M$221.0M$221.0M$221.0M
Retained earnings (deficit)$16.90B$14.91B$28.77B$25.50B$23.82B$21.28B$34.47B$34.06B$31.16B$33.51B
Treasury stock——−$43.77B−$38.62B−$31.26B−$26.24B−$25.36B−$19.57B−$19.25B−$16.78B
Accumulated other comprehensive income−$1.52B−$1.24B−$1.55B−$1.28B−$1.27B−$1.84B−$1.52B−$2.76B−$2.29B−$2.50B
Minority interest$33.0M$53.0M$55.0M$57.0M$60.0M$60.0M$100.0M$96.0M$106.0M$170.0M
Total shareholders' equity$18.47B$16.34B$29.43B$31.06B$35.95B$37.82B$51.60B$14.03B$11.74B$16.18B
Key figures
Total debt$47.14B$51.20B$41.46B$40.72B$45.60B$51.67B$47.54B$7.35B$7.96B$6.71B
Net cash (debt)−$36.47B−$40.34B−$29.18B−$31.46B−$28.38B−$35.22B−$32.15B$1.41B−$1.15B−$358.0M
Working capital$5.97B$6.01B$9.51B$5.38B$11.39B$11.11B$11.05B$7.06B$5.29B$4.86B
Tangible book value−$22.38B−$29.03B−$19.22B−$26.44B−$27.33B−$36.17B−$34.86B$6.40B$3.67B$7.92B
Book value per share$9.05$8.06$14.16$14.47$16.01$16.75$30.14$8.57$7.11$9.63
Shares outstanding2.04B2.03B2.08B2.15B2.25B2.26B1.71B1.64B1.65B1.68B
Current ratio1.261.251.431.251.521.581.601.661.551.55
Quick ratio1.081.061.241.061.361.421.261.361.371.35
Debt / equity2.553.131.411.311.271.370.920.520.680.41
Equity / assets20.5%17.6%30.9%32.1%32.9%31.9%39.7%40.1%35.0%48.0%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 11, 2026); data from EODHD.

BMY financial position

At the end of fiscal 2025 (December 31, 2025), Bristol Myers Squibb had total assets of $90.0 billion (down 2.8% from a year earlier), total liabilities of $71.5 billion and shareholders' equity of $18.5 billion. It held $10.7 billion in cash and short-term investments against $47.1 billion of debt, net debt of $36.5 billion. Its current ratio was 1.26. In the latest quarter (ended June 30, 2026) total assets were $87.6 billion and equity $22.3 billion.

Related: BMY income statement, BMY cash flow statement, BMY key metrics. See the BMY stock overview for the latest quote and news.

BMY balance sheet FAQ

What are Bristol Myers Squibb's total assets?

Bristol Myers Squibb reported total assets of $90.0 billion at the end of fiscal 2025 (December 31, 2025), compared with $92.6 billion a year earlier.

How much debt does Bristol Myers Squibb have?

Bristol Myers Squibb had $47.1 billion of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 2.55.

How much cash does Bristol Myers Squibb have?

Bristol Myers Squibb held $10.7 billion in cash and short-term investments at the end of fiscal 2025; with $47.1 billion of debt that is net debt of $36.5 billion.

What is Bristol Myers Squibb's book value?

Bristol Myers Squibb's shareholders' equity (book value) was $18.5 billion at the end of fiscal 2025, or $9.05 per share.

What is Bristol Myers Squibb's current ratio?

Bristol Myers Squibb had current assets of $29.4 billion and current liabilities of $23.4 billion, a current ratio of 1.26 (it can cover its short-term obligations).

How much goodwill does Bristol Myers Squibb have?

Bristol Myers Squibb carried $40.9 billion of goodwill and intangible assets, 45.4% of total assets, at the end of fiscal 2025.

Drug Manufacturers - General: balance sheet